



bioRxiv is receiving many new papers on coronavirus SARS-CoV-2. A reminder: these are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

New Results

[Comment on this paper](#)

Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region

Adriana Carino, Federica Moraca, Bianca Fiorillo, Silvia Marcanó, Valentina Sepe, Michele Biagioli, Claudia Finamore, Silvia Bozza, Daniela Francisci, Eleonora Distrutti, Bruno Catalanotti, Angela Zampella, Stefano Fiorucci

doi: <https://doi.org/10.1101/2020.06.10.144964>

This article is a preprint and has not been certified by peer review [what does this mean?].

[Abstract](#)

[Info/History](#)

[Metrics](#)

[Preview PDF](#)

Abstract

The coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by the severe acute respiratory syndrome coronavirus (SARS)-CoV-2. In the light of the urgent need to identify novel approaches to be used in the emergency phase, a largely explored strategy has been the repurpose of clinically available drugs as new antivirals, by targeting different viral proteins. In this paper, we describe a drug repurposing strategy based on a virtual screening of druggable pockets located in the central β -sheet core of the SARS-CoV-2 Spike protein RBD supported by in vitro tests identifying several steroidal derivatives as SARS-CoV-2 entry inhibitors. Our results demonstrate that several potential binding sites exist in the SARS CoV-2 S protein, and that the occupancy of these pockets reduces the ability of the S protein RBD to bind to the ACE2 consensus in vitro. In particular, natural occurring and clinically available steroids as

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

[Continue](#)

[Find out more](#)

load. All together, these results might help to define novel approaches to reduce the viral load by using SARS-CoV-2 entry inhibitors.

Competing Interest Statement

This paper was supported by a research grant by BAR Pharmaceuticals S.r.L. to the Department of Pharmacy of the University of Napoli Federico II and to the Department of Surgical and Biomedical Sciences, University of Perugia. The authors declare the following competing financial interest(s): S.F., A.Z. and B.C. have filed an Italian patent application no.10202000011092 in the name of BAR Pharmaceuticals S.r.L. on the compounds described in this paper.

Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Copyright

The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Tweets referencing this article:

COVID-19_arXiv

@COVID19arXiv

Title: Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region. **Authors:** Adriana Carino, Federica Moraca, Bianca Fiorillo, Sil... <https://t.co/5V0zVPnm4N> <https://>

01:50AM

bianca fiorillo

@bianca_fiorillo

Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region | bioRxiv <https://t.co/sVGlrOIc8y>

07:21PM

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

Continue

Find out more

Biochemistry
Bioengineering
Bioinformatics
Biophysics
Cancer Biology
Cell Biology
Clinical Trials*
Developmental Biology
Ecology
Epidemiology*
Evolutionary Biology
Genetics
Genomics
Immunology
Microbiology
Molecular Biology
Neuroscience
Paleontology
Pathology
Pharmacology and Toxicology
Physiology
Plant Biology
Scientific Communication and Education
Synthetic Biology
Systems Biology
Zoology

* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).

Supported by **Chan
Zuckerberg
Initiative** 

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

[Continue](#)

[Find out more](#)

bioRxiv Comment Policy

Comments are moderated for offensive or irrelevant content (can take ~24 hours). Duplicated submission is unnecessary.



Please read our Comment Policy before commenting.

0 Comments bioRxiv Disqus' Privacy Policy

Login ▾

Recommend 1 Tweet Share

Sort by Newest ▾



Start the discussion...

LOG IN WITH

OR SIGN UP WITH DISQUS

Name

Be the first to comment.

Subscribe Add Disqus to your site Add DisqusAdd Do Not Sell My Data

Back to top

Previous

Next

Posted June 11, 2020.

Download PDF

Email

Share

Citation Tools

Tweet

Mi piace 230

COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Subject Area

Pharmacology and Toxicology

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

Continue

Find out more